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OBJECTIVES: Different erythropoiesis-stimulating agents (ESAs) are used to correct 
anaemia in hemodialyzed patients. There is conﬂ icting evidence on whether the dose 
needed to obtain the same hemoglobin level differs between ESAs. This study assessed 
the changes in ESA dose and the differences in cost of treatment when patients were 
switched from epoetin beta (EB) to darbepoetin alfa (DA). METHODS: A mono-
centre retrospective chart review was performed. All hemodialysis patients switched 
from EB to DA during the ﬁ rst week of January 2008. The dose conversion from EB 
to used was 200 IU:1 μg based on the European DA label. In patients dialyzed for at 
least 9 months at conversion, ESA dose and hemoglobin level were collected 3 months 
prior (baseline) to 12 months after conversion. The ratio “average weekly ESA dose/
average weekly hemoglobin level”, the average weekly ESA-drug-related cost per 
patient (Belgian public payer’s perspective), the average weekly dose of ESA and the 
average weekly hemoglobin were compared for the baseline period vs. weeks 14–26 
and 40–52 post-switch using the Wilcoxon signed rank test. RESULTS: Out of 144 
screened patients, 96 were eligible and survived without renal transplantation until 
week 52. The ratio “average weekly ESA dose/average weekly hemoglobin level” 
decreased from 611 IU/g/dL to respectively 359 IU/g/dL and 348 IU/g/dL in the 
deﬁ ned post-switch periods (P < 0.0001), without any change in average hemoglobin. 
a substantial reduction in drug cost was observed after switch (from c66.8 to c53.6 
and c52.8/week). The average weekly ESA dose decreased from baseline to post-switch 
from 7230 IU to 4203 IU and 4137 IU (P < 0.0001). Both ESA dosing and hemoglobin 
were stabilised after a 13-weeks titration period post-switch. CONCLUSIONS: 
Switching patients from EB to DA resulted in a signiﬁ cant decrease of the ESA dose 
needed to obtain the same hemoglobin level. This signiﬁ cant decrease in dosage 
resulted in a substantial decrease in drug costs.
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OBJECTIVES: Risk and consequences of inhibitor (antibodies) development in 
patients with hemophilia are the main safety issue in patients treated with recombinant 
drugs, due to its impact on health and quality of patient’s life. The objective of this 
study is to quantify the economical impact of treating A-hemophiliac patients develop-
ing inhibitors against factor VIII (FVIII) for the National Health System (NHS) in 
Spain. METHODS: An economical model was built as a decision tree allowing assign-
ing the resource use to handle inhibitor development and its associated cost in different 
patient groups according to its age, treatment pattern and response proﬁ le. Data was 
obtained from a literature review and validated by an experts’ panel. a one-way 
sensitivity analysis was performed to check for results robustness. RESULTS: The 
mean annual cost per patient suffering from severe hemophilia a developing inhibitors 
against FVIII in Spain was c567,518 (EUR 2009), 99% due to pharmacological costs. 
Results show an important variability, from c166,845 to c2,408,486 depending on 
the type of patient: its age related to its weight and adequate treatment dosage, its 
inhibitors’ titer (low or high-titer) and its treatment (on demand or to eradicate inhibi-
tors). The number of bleeding episodes was the variable with the greatest impact on 
results. According to population data and illness incidence, a 5% increase on the risk 
of inhibitor development implies a new case per year in Spanish population and, 
therefore, an expenditure of more than half a million Euro for the NHS. CONCLU-
SIONS: This study analyzes for the ﬁ rst time the cost of inhibitors’ development 
among patients with severe hemophilia a treated with recombinant FVIII from the 
perspective of the Spanish NHS. Results show that treatments to overcome this safety 
issue represent an important economical burden, so that strategies preventing from 
inhibitor development should be implemented in this population.
PSY29
DARBEPOETIN ALFA VERSUS EPOETIN ALFA FOR TREATMENT OF 
CHEMOTHERAPY-INDUCED ANEMIA: A HEALTH ECONOMIC 
EVALUATION
Finek J1, Holubec L1, Wiesnerova A1, Pav Z1, Dusek L2
1Teaching Hospital and Medical Faculty of Charles University, Plzen, Czech Republic; 
2Masaryk University Brno, Brno, Czech Republic
OBJECTIVES: Erythropoiesis-stimulating proteins (ESPs) are used in the treatment of 
chemotherapy-induced anemia (CIA) with the aim of improving quality of life and 
reducing the need for blood transfusions. a retrospective analysis based on data from 
a single institution compared costs and effectiveness of two ESPs, epoetin alfa and 
darbepoetin alfa, in consecutively treated patients over a 2-year period. METHODS: 
Data from all patients treated for CIA between January 1, 2007 and December 31, 
2008 with one of the two ESPs—epoetin alfa- (40 000 IU once weekly) or darbepoetin 
alfa- (500 μg every 3 weeks)—were analyzed. Total and per patient costs and costs 
per clinical response (hemoglobin ≥ 11 g/dL) were calculated, based on drug acquisi-
tion costs for the ESPs. RESULTS: A total of 161 patients were treated with epoetin 
alfa (799 doses; mean 4.96 doses per patient) and 52 with darbepoetin alfa (94 doses; 
mean 1.81 doses per patient). Total and per-patient costs were 8,682,226 CZK 
(c331,003.66) and 54,461 CZK (c2076.29) for epoetin alfa versus 2,578,984 CZK 
(c98,321.92) and 49,596 CZK (c1,890.81) for darbepoetin alfa. The response rate 
was higher (58% vs. 47%, not statistically signiﬁ cant), and the mean cost per treat-
ment response was lower, with darbepoetin alfa, at 85,966 CZK (c3,277.39) versus 
115,763 CZK (c4,413.38) for epoetin alfa. CONCLUSIONS: Our results indicate that 
darbepoetin alfa is associated with lower drug acquisition costs than epoetin alfa, as 
well as a lower cost per treatment response, for treatment of CIA.
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OBJECTIVES: Spinal Cord Stimulation (SCS) is considered to be an effective therapy 
for patients affected by Failed Back Surgery Syndrome refractory to conventional 
medical management (CMM). PRECISE Study aims to evaluate the costs and clinical 
beneﬁ ts of SCS (plus CMM) versus CMM alone on a 2-year horizon in Italy. Here 
12-months results are reported. METHODS: PRECISE Study is an observational, 
pre-post, multi-centre study. Eighty patients were enrolled to be screened for SCS and, 
if responders, to be implanted. Health care and non-health care resources use and 
costs, clinical outcomes and HR-QoL data were collected before and after the implan-
tation. The 12-months data was analyzed and compared to pre-implantation results. 
Mean monthly resources use, costed in euros 2008, was evaluated according to three 
perspectives: patient, National Healthcare System (NHS), Society. RESULTS: Seventy-
two (90%) patients responded to screening and were implanted. Out of them, 62 
(mean age 57; 61% female) completed the 12-months follow-up; ten patients discon-
tinued the therapy for: therapy failure (10%), complications/technical issues (60%), 
other reasons (30%). SCS signiﬁ cantly reduced pain, and improved function and 
HR-QoL: mean pain intensity decreased from 7.4 ± 1.3 to 4.4 ± 2.5 (pain Numerical 
Rating Scale), 53 patients (85%) experienced an improvement in function measured 
with Oswestry Disability Index and EQ-VAS increased from 37 to 59. The mean utility 
score was 0.49 (baseline: 011). Patient’s monthly out-of-pocket expenditure halved 
from c161.45 to c80.04. Excluding upfront costs (screening and implantation), total 
NHS monthly per-patient expenditure diminished from c163.77 to c100.17, Society 
monthly per-patient expenditure from c461.89 to c253.27. Including them, NHS 
and Societal monthly costs per-patient were c1,318.30 and c1,471.40, respectively. 
CONCLUSIONS: SCS with CMM is more effective than CMM alone in controlling 
pain and improving HR-QoL. Excluding the upfront costs related to the implantation, 
SCS allows a reduction in resources consumption and productivity losses from all the 
possible perspectives of analysis (patient, NHS, Society).
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OBJECTIVES: Invasive fungal infections (IFI) remain a clinical concern in hematologi-
cal cancer patients with prolonged neutropenia because they are major cause of 
morbidity and mortality. As a result, the guidelines of the International Society of 
Infectious Diseases recommend adequate prophylaxis while the patient remains neu-
tropenic. In this study, a cost-effectiveness analysis was conducted to measure the 
economic value of posaconazole as an alternative to ﬂ uconazole or itraconazole when 
used to prevent IFI in this patent population. METHODS: A decision analysis model 
was developed using clinical and economic data from randomized comparative trials, 
the economic literature and from expert opinion. The data were then used to estimate 
the incremental cost per life-year saved with oral posaconazole prophylaxis relative 
to ﬂ uconazole or itraconazole from the Canadian provincial health care system per-
spective. The base-case results were then tested with an extensive sensitivity analysis 
which evaluated extremes in the incidence of IFI as well as variations in their cost of 
management. RESULTS: The base-case ﬁ ndings revealed that prophylaxis with 
posaconazole provides at least comparable efﬁ cacy and an overall cost savings of 
approximately $4260 per patient. Despite variations in the base-case parameters, the 
sensitivity analysis suggested stability in the primary ﬁ ndings. Posaconazole was asso-
ciated with an overall cost savings (range = $1765 to $5118) and at least comparable 
beneﬁ t. Optimal cost-effectiveness was obtained when the drug was able to avoid more 
invasive Aspergillus infections. CONCLUSIONS: Prophylaxis with posaconazole in 
neutropenic hematological cancer patients is not only cost-effective but also cost 
saving. The economic beneﬁ ts were due to the drug’s ability to reduce the incidence 
of high cost fungal infections, particularly Aspergillus species.
